98 related articles for article (PubMed ID: 1326165)
1. [Results of clinico-immunological testing of myelopid in chronic forms of multiple sclerosis].
Gusev EI; Demina TL; Boĭko AN; Popova NF; Stepanenko RN
Zh Nevropatol Psikhiatr Im S S Korsakova; 1992; 92(2):18-25. PubMed ID: 1326165
[TBL] [Abstract][Full Text] [Related]
2. [Clinico-immunological monitoring of the condition of patients with multiple sclerosis].
Gusev EI; Demina TL; Boĭko AN; Tatarinova MIu
Zh Nevropatol Psikhiatr Im S S Korsakova; 1992; 92(2):14-8. PubMed ID: 1326164
[TBL] [Abstract][Full Text] [Related]
3. [Indicators of cellular immunity in patients with multiple sclerosis].
Dziuba AN; Frolov VM; Gaĭdash IS
Zh Nevropatol Psikhiatr Im S S Korsakova; 1992; 92(2):12-4. PubMed ID: 1326155
[TBL] [Abstract][Full Text] [Related]
4. Correlation of immunological studies and disease progression in chronic progressive multiple sclerosis.
Trotter JL; Clifford DB; McInnis JE; Griffeth RC; Bruns KA; Perlmutter MS; Anderson CB; Collins KG; Banks G; Hicks BC
Ann Neurol; 1989 Feb; 25(2):172-8. PubMed ID: 2521993
[TBL] [Abstract][Full Text] [Related]
5. [Experience in using T-activin in multiple sclerosis patients].
Gusev EI; Arion VIa; Aristova RA; Ivanokov AN; Tunkel' OI
Zh Nevropatol Psikhiatr Im S S Korsakova; 1984; 84(2):168-74. PubMed ID: 6608843
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of myelopid in immunodeficiency states].
Petrov RV; Borisova AM; Glazko AV; Simonova AV; Stepanenko RN
Ter Arkh; 1990; 62(12):81-7. PubMed ID: 2084931
[No Abstract] [Full Text] [Related]
7. [Role of immunoregulatory cells and natural killers in the pathogenesis of multiple sclerosis].
Tunkel' OI; Saidov MZ; Cheredeev AN; Koval'chuk LV; Skriabina EG
Zh Nevropatol Psikhiatr Im S S Korsakova; 1983; 83(6):880-5. PubMed ID: 6224384
[TBL] [Abstract][Full Text] [Related]
8. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
[TBL] [Abstract][Full Text] [Related]
9. [Use of myelopid in the complex treatment of patients with destructive pulmonary tuberculosis].
Vakhidova GA; Vasil'eva FR; Kurbanova RR; Stepanenko RN; Ubaĭdullaev AM
Probl Tuberk; 1990; (3):16-8. PubMed ID: 2367502
[TBL] [Abstract][Full Text] [Related]
10. Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind study.
Joshi SS; Bishop MR; Lynch JC; Tarantolo SR; Abhyankar S; Bierman PJ; Vose JM; Geller RB; McGuirk J; Foran J; Bociek RG; Hadi A; Day SD; Armitage JO; Kessinger A; Pavletic ZS
Cytotherapy; 2003; 5(6):542-52. PubMed ID: 14660050
[TBL] [Abstract][Full Text] [Related]
11. [Cytokine-secreting cells in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone].
Yagi Y; Takahashi M; Nakamura Y
Rinsho Shinkeigaku; 1997 Jul; 37(7):575-9. PubMed ID: 9396353
[TBL] [Abstract][Full Text] [Related]
12. Limited effect of eicosapentaenoic acid on T-lymphocyte and natural killer cell numbers and functions in healthy young males.
Miles EA; Banerjee T; Wells SJ; Calder PC
Nutrition; 2006 May; 22(5):512-9. PubMed ID: 16600816
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effect of vitamin D3 in multiple sclerosis patients.
Mosayebi G; Ghazavi A; Ghasami K; Jand Y; Kokhaei P
Immunol Invest; 2011; 40(6):627-39. PubMed ID: 21542721
[TBL] [Abstract][Full Text] [Related]
14. Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis.
Janiec K; Wajgt A; Kondera-Anasz Z
Med Sci Monit; 2001; 7(1):93-8. PubMed ID: 11208501
[TBL] [Abstract][Full Text] [Related]
15. [Characteristics of cellular immunity in multiple sclerosis].
Demina TL; Boĭko AN; Balashov KE; Pinegin BV
Zh Nevropatol Psikhiatr Im S S Korsakova; 1989; 89(2):35-41. PubMed ID: 2524943
[TBL] [Abstract][Full Text] [Related]
16. Normal T cell subsets and lymphocyte activity in multiple sclerosis.
Albala MM; Davignon D; Fast LD; Clark DD
Clin Exp Immunol; 1985 Sep; 61(3):542-7. PubMed ID: 3878242
[TBL] [Abstract][Full Text] [Related]
17. [Immunologic correction in the treatment of chronic hematogenic osteomyelitis of long tubular bones in children].
Samsygin SA; Schastnyĭ SA; Vlasenko VV; Dolgina EN; Ekk ND
Vestn Akad Med Nauk SSSR; 1991; (12):50-4. PubMed ID: 1801475
[TBL] [Abstract][Full Text] [Related]
18. Immunological parameters in multiple sclerosis patients with special reference to the herpes virus group.
Haahr S; Møller-Larsen A; Pedersen E
Clin Exp Immunol; 1983 Feb; 51(2):197-206. PubMed ID: 6188564
[TBL] [Abstract][Full Text] [Related]
19. Low-dose (7.5 mg) oral methotrexate for chronic progressive multiple sclerosis. Design of a randomized, placebo-controlled trial with sample size benefits from a composite outcome variable including preliminary data on toxicity.
Goodkin DE; Rudick RA; VanderBrug Medendorp S; Greene T; Schwetz KM; Fischer J; Daughtry MM; Ross J; Van Dyke C
Online J Curr Clin Trials; 1992 Sep; Doc No 19():[7723 words; 89 paragraphs]. PubMed ID: 1343611
[TBL] [Abstract][Full Text] [Related]
20. [Functional properties of T-lymphocytes in patients with multiple sclerosis].
Zleleznova TA; Ierusalimskiĭ AP
Zh Nevropatol Psikhiatr Im S S Korsakova; 1989; 89(7):19-23. PubMed ID: 2529722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
